Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Medpace Holdings, Inc. (Nasdaq: MEDP), a scientifically driven, global, full-service clinical contract research organization (CRO). Through these filings, investors can review the company’s official financial statements, risk disclosures, material agreements and other regulatory information that frame analysis of MEDP stock.
Medpace’s SEC reporting includes annual reports on Form 10-K, which contain audited financial statements, management’s discussion and analysis, and a detailed “Risk Factors” section describing uncertainties such as contract loss, backlog conversion, pricing pressure, international operations, regulatory compliance, and information systems risks. Quarterly reports on Form 10-Q provide interim financial updates and additional context on operating performance in the clinical research and development services business.
The company also files current reports on Form 8-K to disclose specific events. For example, Medpace has used Form 8-K to furnish earnings press releases under Item 2.02 and to describe amendments to its unsecured credit facility under Item 1.01, including changes to the aggregate principal amount available under its line of credit. These filings give detail on financing arrangements and other material developments beyond the headline numbers in press releases.
On Stock Titan, Medpace filings are paired with AI-powered summaries that highlight key points from lengthy documents, such as major changes in revenue and profitability, updates to guidance, or notable shifts in risk disclosures. Users can quickly scan 10-K and 10-Q reports, as well as 8-K items, while retaining the option to open the full SEC documents for deeper review. This page also surfaces information relevant to tracking management decisions, capital structure, and other regulatory matters that influence Medpace’s long-term profile as a global CRO.
Medpace Holdings, Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act. MEDP’s common stock trades on the NASDAQ Global Select Market.
Robert O. Kraft, a director of Medpace Holdings, Inc. (MEDP), reported a securities transaction on 09/30/2025. The filing shows 57 restricted stock units vested and were reported as delivered, arising from a 227-unit grant made on 11/29/2024 that vests in four approximately equal installments on 03/31/2025, 06/30/2025, 09/30/2025 and 12/31/2025. Each restricted stock unit represents the right to receive one share of MEDP common stock. After the reported transaction the form lists 833 shares of common stock beneficially owned by the reporting person.
Cornelius P. McCarthy III, a director of Medpace Holdings, Inc. (MEDP), reported a vesting-related transaction dated 09/30/2025. 49 restricted stock units converted into 49 shares of common stock at $0 consideration, and the report shows the reporting person beneficially owns 10,246 shares following the transaction. The restricted stock units stem from a grant of 198 RSUs on 11/29/2024 that vest in four approximately equal installments on 3/31/2025, 6/30/2025, 9/30/2025, and 12/31/2025.
This Form 4 indicates a routine vesting event rather than an open-market purchase or sale; the transaction code is reported as "M" for vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Susan E. Burwig, Executive Vice President, Operations at Medpace Holdings, Inc. (MEDP), exercised employee stock options to acquire 10,000 shares on 09/26/2025 at an exercise price of $107.93 per share. The filing states the option vested in full on 02/28/2020. The Form 4 lists 67,500 shares as the amount of common stock beneficially owned following the non-derivative transaction and lists 30,984 shares as the number of derivative securities beneficially owned following the derivative transaction. The form is signed by an attorney-in-fact on behalf of Ms. Burwig on 09/30/2025.
Medpace Holdings insider transaction summary — An officer and director, Susan E. Burwig, reported a sale of 10,000 shares of Medpace common stock executed pursuant to a limit order during an open trading window; the reported weighted-average sale price was $480.00 (transactions ranged $480.00–$480.09). After the sale, the reporting person beneficially owned 57,500 shares. The filer notes availability of full pricing detail upon request. No derivative transactions or other changes in beneficial ownership are reported.
Medpace Holdings, Inc. (MEDP) Form 144 notice shows an intended sale of 10,000 common shares through Fidelity Brokerage Services on 09/03/2025 with an aggregate market value of $4,800,019.30. The shares were acquired by the seller via a stock option exercise on 08/05/2024 and paid in cash. The filing reports 28,093,026 shares outstanding. The same person sold 7,500 shares on 07/28/2025 for gross proceeds of $3,376,083.14. The filer attests there is no undisclosed material adverse information and includes the required sale and acquisition details.
August J. Troendle, CEO, director and reported 10% owner of Medpace Holdings, Inc. (MEDP), reported open-market sales of common stock executed pursuant to a limit order during an open window period. On 08/29/2025 he sold 36,196 shares at a weighted average price reported as $475.9, leaving 925,799 shares directly beneficially owned. On 09/02/2025 he sold 1,197 shares at a weighted average price reported as $475.11, leaving 924,602 shares directly owned. He also may be deemed to indirectly own 4,733,019 shares held by Medpace Investors, LLC, of which he is sole manager with voting and investment control. The form was signed by an attorney-in-fact on 09/03/2025.
Form 144/A from Medpace Holdings, Inc. (MEDP) reports a proposed sale of 38,013 common shares through UBS Financial Services on 08/27/2025 with an aggregate market value of $18,056,175.00. The shares were acquired on 02/15/2022 by option exercise from the issuer and paid for in cash on 03/01/2022. The filing lists 28,741,609 shares outstanding for the class. The notice also discloses a recent sale by August J Troendle of 48,487 shares on 07/28/2025 for gross proceeds of $21,900,851.00. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal warnings.
August J. Troendle, CEO, director and reported 10% owner of Medpace Holdings, Inc. (MEDP) reported a sale of 620 shares of the issuer's common stock on 08/27/2025 at $475 per share executed pursuant to a limit order placed during an open window period. After the sale the reporting person directly beneficially owns 961,995 shares and is reported as indirectly owning 4,733,019 shares through Medpace Investors, LLC, of which he is sole manager and controlling unit holder.
The filing clarifies that Troendle disclaims beneficial ownership of MPI-held shares except to the extent of his pecuniary interest and the Form 4 was signed by an attorney-in-fact on 08/28/2025.
Medpace Holdings insider transaction: Susan E. Burwig, Executive Vice President, Operations, reported exercising employee stock options and acquiring 10,000 shares of Medpace Holdings, Inc. (MEDP) on 08/26/2025 at a price of $107.93 per share. After the transaction she beneficially owns 67,500 shares directly. The filing also reports outstanding derivative holdings tied to employee stock options that reference 10,000 underlying shares and show 40,984 derivative securities beneficially owned following the reported activity. The form is signed by an attorney-in-fact on 08/28/2025.